CSPC's RSV vaccine clears FDA for US trials weeks after China approval

CSPC Pharmaceutical Group's RSV vaccine candidate SYS6057 received FDA clearance to begin US clinical trials shortly after approval in China, aiming at preventing RSV-associated lower respiratory tract disease in adults aged 60 and older and competing in a market with GSK, Pfizer, and Moderna vaccines.

This Wire brief sits within Fusion42's coverage of Biotech.